^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MT-0169

    i
    Other names: MT-0169, TAK-169, Engineered Toxin Bodies Targeting CD38
    Company:
    Molecular Templates
    Drug class:
    CD38 inhibitor, Protein synthesis inhibitor
    Related drugs:
    4ms
    MT-0169-001: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=14, Terminated, Molecular Templates, Inc. | N=54 --> 14 | Trial completion date: Dec 2024 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2023; Sparse/no patient enrollment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    MT-0169
    6ms
    MT-0169-001: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Molecular Templates, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MT-0169
    6ms
    MT-0169-001: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=54, Recruiting, Molecular Templates, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    MT-0169
    7ms
    MT-0169-001: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Molecular Templates, Inc. | N=144 --> 54 | Trial primary completion date: Jan 2024 --> Aug 2024
    Enrollment change • Trial primary completion date
    |
    MT-0169
    1year
    Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile (AACR 2023)
    Three ETBs (MT-0169, MT-5111, and MT-6402) are currently in clinical studies across different targets (CD38, HER2, PD-L1) and across hematologic malignancies, solid tumor, and immuno-oncology indications. ETBs can also deliver additional payloads to drive unique biology like the alteration of tumor immunophenotype. Here we describe three active clinical stage programs with encouraging safety and efficacy data that represent a transformation of the immunotoxin landscape into a more viable therapeutic approach to target validated as well as typically intractable clinical cancer targets.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    MT-5111 • MT-6402 • MT-0169
    over2years
    A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients with Relapsed or Refractory Multiple Myeloma (ASH 2021)
    Clinical activity was seen in heavily pre-treated hematological malignancies with a first-generation ETB (MT-3724) targeting CD20...Prior treatment with an anti-CD38 therapy (including daratumumab) is permitted...The trial is currently recruiting at three US sites. (NCT04017130)
    Clinical • P1 data • PK/PD data
    |
    CD59 (CD59 Molecule)
    |
    Darzalex (daratumumab) • MT-0169 • MT-3724